Emerging drugs for bacterial urinary tract infections

Expert Opinion on Emerging Drugs

Volumn 15, Issue 3, 2010, Pages 375-397

  Wagenlehner, Florian Me ^a   Weidner, Wolfgang ^a   Perletti, Gianpaolo ^c   Naber, Kurt G ^b  

^a UNIVERSITY HOSPITAL GIESSEN   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

Antibiotic resistance; Antiinfective substances; New antimicrobials; Urinary tract infections; Uropathogens

Indexed keywords

AMIKACIN; AMINOPENICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFEPIME; CEFOTAXIME; CEFPODOXIME PROXETIL; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CLOTRIMAZOLE; ERTAPENEM; FOSFOMYCIN TROMETAMOL; GENTAMICIN; LEVOFLOXACIN; MECILLINAM; MEROPENEM; NITROFURANTOIN; NORFLOXACIN; OFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; PIVMECILLINAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TRIMETHOPRIM; TROMETAMOL; UNINDEXED DRUG;

ANAPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL INFECTION; CLINICAL TRIAL; CYSTIC FIBROSIS; CYSTITIS; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; ENVIRONMENTAL FACTOR; HEART ARRHYTHMIA; HUMAN; MEDICAL RESEARCH; NONHUMAN; PYELONEPHRITIS; REVIEW; TENDON RUPTURE; TREATMENT DURATION; TREATMENT OUTCOME; URINARY TRACT INFECTION;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS, URINARY; BACTERIAL INFECTIONS; DRUG DESIGN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUGS, INVESTIGATIONAL; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; URINARY TRACT INFECTIONS;

EID: 77955855655     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.2010.500613     Document Type: Review

References (85)

1. Falagas ME, Kotsantis IK, Vouloumanou EK, Rafailidis PI. Antibiotics versus placebo in the treatment of women with uncomplicated cystitis: a meta-analysis of randomized controlled trials. J Infect 2009;58(2):91-102
2. Johnson L, Sabel A, Burman WJ, et al. Emergence of fluoroquinolone resistance in outpatient urinary Escherichia coli isolates. Am J Med 2008;121(10):876-884
3. Naber KG, Schito G, Botto H, et al. Surveillance study in Europe and Brazil on clinical aspects and antimicrobial resistance epidemiology in females with cystitis (ARESC): implications for empiric therapy. Eur Urol 2008;54(5):1164-1175
4. Owens RC Jr, Donskey CJ, Gaynes RP, et al. Antimicrobial-associated risk factors for clostridium difficile infection. Clin Infect Dis 2008;46(Suppl 1):S19-31
5. Warren JW, Abrutyn E, Hebel JR, et al. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis 1999;29(4):745-758
6. Johansen TE, Cek M, Naber KG, et al. Hospital acquired urinary tract infections in urology departments: pathogens, susceptibility and use of antibiotics. Data from the PEP and PEAP-studies. Int J Antimicrob Agents 2006;28(Suppl 1):S91-107
7. Bent S, Saint S. The optimal use of diagnostic testing in women with acute uncomplicated cystitis. Am J Med 2002;113(Suppl 1A):20S-8S
8. Tambic A, Tambic T, Kucisec-Tepes N. Prevalence and antibiotic sensitivity pattern variations of bacterial isolates in different settings and different periods of time. Acta Med Croatica 1996;50:5-10
9. Jones RN, Kugler KC, Pfaller MA, Winokur PL. Characteristics of pathogens causing urinary tract infections in hospitals in North America: results from the SENTRY antimicrobial surveillance program, 1997. Diagn Microbiol Infect Dis 1999;35(1):55-63
10. Mathai D, Jones RN, Pfaller MA. Epidemiology and frequency of resistance among pathogens causing urinary tract infections in 1,510 hospitalized patients: a report from the SENTRY Antimicrobial Surveillance Program (North America). Diagn Microbiol Infect Dis 2001;40(3):129-136
11. Elhanan G, Sarhat M, Raz R. Empiric antibiotic treatment and the misuse of culture results and antibiotic sensitivities in patients with community-acquired bacteraemia due to urinary tract infection. J Infect 1997;35(3):283-288
12. Investigational Drugs Data Base, Current Drugs, Ltd. Available from: http://www.iddb3.com
13. Hooton TM, Scholes D, Gupta K, et al. Amoxicillin-clavulanate vs ciprofloxacin for the treatment of uncomplicated cystitis in women: a randomized trial. JAMA 2005;293(8):949-955
14. Leigh AP, Nemeth MA, Keyserling CH, et al. Cefdinir versus cefaclor in the treatment of uncomplicated urinary tract infection. Clin Ther 2000;22(7):818-825
15. Kavatha D, Giamarellou H, Alexiou Z, et al. Cefpodoxime-proxetil versus trimethoprim-sulfamethoxazole for short-term therapy of uncomplicated acute cystitis in women. Antimicrob Agents Chemother 2003;47(3):897-900
16. Naber KG, Koch EM. Cefuroxime axetil versus ofloxacin for short-term therapy of acute uncomplicated lower urinary tract infections in women. Infection 1993;21(1):34-39
17. Auquer F, Cordon F, Gorina E, et al. Single-dose ciprofloxacin versus 3 days of norfloxacin in uncomplicated urinary tract infections in women. Clin Microbiol Infect 2002;8(1):50-54
18. McCarty JM, Richard G, Huck W, et al. A randomized trial of short-course ciprofloxacin, ofloxacin, or trimethoprim/ sulfamethoxazole for the treatment of acute urinary tract infection in women. Ciprofloxacin Urinary Tract Infection Group. Am J Med 1999;106(3):292-299
19. Iravani A, Klimberg I, Briefer C, et al. A trial comparing low-dose, short-course ciprofloxacin and standard 7 day therapy with co-trimoxazole or nitrofurantoin in the treatment of uncomplicated urinary tract infection. J Antimicrob Chemother 1999;43(Suppl A):67-75
20. Iravani A, Tice AD, McCarty J, et al. Short-course ciprofloxacin treatment of acute uncomplicated urinary tract infection in women. The minimum effective dose. The Urinary Tract Infection Study Group [corrected]. Arch Intern Med 1995;155(5):485-494
21. Vogel T, Verreault R, Gourdeau M, et al. Optimal duration of antibiotic therapy for uncomplicated urinary tract infection in older women: a double-blind randomized controlled trial. CMAJ 2004;170(4):469-473
22. Arredondo-Garcia JL, Figueroa-Damian R, Rosas A, et al. Comparison of short-term treatment regimen of ciprofloxacin versus long-term treatment regimens of trimethoprim/ sulfamethoxazole or norfloxacin for uncomplicated lower urinary tract infections: a randomized, multicentre, open-label, prospective study. J Antimicrob Chemother 2004;54(4):840-843
23. Henry DC Jr, Bettis RB, Riffer E, et al. Comparison of once-daily extended-release ciprofloxacin and conventional twice-daily ciprofloxacin for the treatment of uncomplicated urinary tract infection in women. Clin Ther 2002;24(12):2088-2104
24. Fourcroy JL, Berner B, Chiang YK, et al. Efficacy and safety of a novel once-daily extended-release ciprofloxacin tablet formulation for treatment of uncomplicated urinary tract infection in women. Antimicrob Agents Chemother 2005;49(10):4137-4143
25. Backhouse CI, Matthews JA. Single-dose enoxacin compared with 3-day treatment for urinary tract infection. Antimicrob Agents Chemother 1989;33(6):877-880
26. Iravani A. Multicenter study of single-dose and multiple-dose fleroxacin versus ciprofloxacin in the treatment of uncomplicated urinary tract infections. Am J Med 1993;94(3A):89S-96S
27. Iravani ACP, Maladorno D. Fleroxacin in the treatment of uncomplicated urinary tract infections in women. 7th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); 26-30 March 1995; Vienna, Austria; 1995
28. Jardin A. A general practitioner multicenter study: fosfomycin trometamol single dose versus pipemidic acid multiple dose. Infection 1990;18(Suppl 2):S89-93
29. Boerema JB, Willems FT. Fosfomycin trometamol in a single dose versus norfloxacin for seven days in the treatment of uncomplicated urinary infections in general practice. Infection 1990;18(Suppl 2):S80-8
30. de Jong Z, Pontonnier F, Plante P. Single-dose fosfomycin trometamol (Monuril) versus multiple-dose norfloxacin: results of a multicenter study in females with uncomplicated lower urinary tract infections. Urol Int 1991;46(4):344-348
31. Van Pienbroek E, Hermans J, Kaptein AA, Mulder JD. Fosfomycin trometamol in a single dose versus seven days nitrofurantoin in the treatment of acute uncomplicated urinary tract infections in women. Pharm World Sci 1993;15(6):257-262
32. Lecomte F, Allaert FA. Le traitement monodose de la cystite par fosfomycin trometamol. Analyse de 15 essais comparatifs portant sur 2048 malades. Medecine et Maladies infectieuses. 1996;26:338-343
33. Lecomte F, Allaert FA. Single-dose treatment of cystitis with fosfomycin trometamol (Monuril): Analysis of comparative trials on 2.048 patients. Giorn It Ost Gin 1997;19:399-404 (Pubitemid 28037585)
34. Minassian MA, Lewis DA, Chattopadhyay D, et al. A comparison between single-dose fosfomycin trometamol (Monuril) and a 5-day course of trimethoprim in the treatment of uncomplicated lower urinary tract infection in women. Int J Antimicrob Agents 1998;10(1):39-47
35. Stein GE. Comparison of single-dose fosfomycin and a 7-day course of nitrofurantoin in female patients with uncomplicated urinary tract infection. Clin Ther 1999;21(11):1864-1872
36. Bonfiglio G, Mattina R, Lanzafame A, et al. Fosfomycin tromethamine in uncomplicated urinary tract infections: a clinical study. Chemotherapy 2005;51(2-3):162-166
37. Richard GA, Mathew CP, Kirstein JM, et al. Single-dose fluoroquinolone therapy of acute uncomplicated urinary tract infection in women: results from a randomized, double-blind, multicenter trial comparing single-dose to 3-day fluoroquinolone regimens. Urology 2002;59(3):334-339
38. Naber KG, Allin DM, Clarysse L, et al. Gatifloxacin 400 mg as a single shot or 200 mg once daily for 3 days is as effective as ciprofloxacin 250 mg twice daily for the treatment of patients with uncomplicated urinary tract infections. Int J Antimicrob Agents 2004;23(6):596-605
39. Richard GA, DeAbate CA, Ruoff GE, Corrado M, et al. A double-blind, randomised trial of the efficacy and safety of short-course, once-daily levofloxacin versus ofloxacin twice daily in uncomplicated urinary tract infection. Infect Dis Clin Pract 1998;9:323-329
40. Richard G, deAbate C, Ruoff G, et al. Short-course levofloxacin (250 mg qid) vs ofloxacin (200 mg bid) in uncomplicated UTI: a double-blind, randomized trial. Abstract. 6th Int Symp New Quinolones; Nov 15-17, 1998; Denver, Colorado, USA; Nov 15-17, 1998
41. Neringer R, Forsgren A, Hansson C, Ode B. Lomefloxacin versus norfloxacin in the treatment of uncomplicated urinary tract infections: three-day versus seven-day treatment. The South Swedish Lolex Study Group. Scand J Infect Dis 1992;24(6):773-780
42. Nicolle LE, DuBois J, Martel AY, et al. Treatment of acute uncomplicated urinary tract infections with 3 days of lomefloxacin compared with treatment with 3 days of norfloxacin. Antimicrob Agents Chemother 1993;37(3):574-579
43. Goettsch WG, Janknegt R, Herings RM. Increased treatment failure after 3-days' courses of nitrofurantoin and trimethoprim for urinary tract infections in women: a population-based retrospective cohort study using the PHARMO database. Br J Clin Pharmacol 2004;58(2):184-189
44. Gupta K, Hooton TM, Roberts PL, Stamm WE. Short-course nitrofurantoin for the treatment of acute uncomplicated cystitis in women. Arch Intern Med 2007;167(20):2207-2212
45. Spencer RC, Moseley DJ, Greensmith MJ. Nitrofurantoin modified release versus trimethoprim or co-trimoxazole in the treatment of uncomplicated urinary tract infection in general practice. J Antimicrob Chemother 1994;33(Suppl A):121-129
46. Double-blind comparison of 3-day versus 7-day treatment with norfloxacin in symptomatic urinary tract infections. The Inter-Nordic Urinary Tract Infection Study Group. Scand J Infect Dis 1988;20(6):619-624
47. Piipo TPT, Salo SA. Three-day versus seven-day treatment with norfloxacin in acute cystitis. Curr Ther Res 1990;47:644-653
48. Pimentel FL, Dolgner A, Guimaraes J, et al. Efficacy and safety of norfloxacin 800 mg once-daily versus norfloxacin 400 mg twice-daily in the treatment of uncomplicated urinary tract infections in women: a double-blind, randomized clinical trial. J Chemother 1998;10(2):122-127
49. Block JM, Walstad RA, Bjertnaes A, et al. Ofloxacin versus trimethoprim-sulphamethoxazole in acute cystitis. Drugs 1987;34(Suppl 1):100-106
50. Hooton TM, Latham RH, Wong ES, et al. Ofloxacin versus trimethoprim-sulfamethoxazole for treatment of acute cystitis. Antimicrob Agents Chemother 1989;33(8):1308-1312
51. Hooton TM, Johnson C, Winter C, et al. Single-dose and three-day regimens of ofloxacin versus trimethoprim-sulfamethoxazole for acute cystitis in women. Antimicrob Agents Chemother 1991;35(7):1479-1483
52. Naber KG, Baurecht W, Fischer M, Kresken M. Pefloxacin single-dose in the treatment of acute uncomplicated lower urinary tract infections in women: a meta-analysis of seven clinical trials. Int J Antimicrob Agents 1994;4:197-202
53. Kadiri S, Ajayi SO, Toki RA. Quinolones for short-term treatment of uncomplicated urinary tract infection. East Afr Med J 1999;76(10):587-589
54. Menday AP. Comparison of pivmecillinam and cephalexin in acute uncomplicated urinary tract infection. Int J Antimicrob Agents 2000;13(3):183-187
55. Nicolle LE. Pivmecillinam in the treatment of urinary tract infections. J Antimicrob Chemother 2000;46(Suppl 1):35-9; discussion 63-65
56. Nicolle LE, Madsen KS, Debeeck GO, et al. Three days of pivmecillinam or norfloxacin for treatment of acute uncomplicated urinary infection in women. Scand J Infect Dis 2002;34(7):487-492
57. Menday AP. Symptomatic vaginal candidiasis after pivmecillinam and norfloxacin treatment of acute uncomplicated lower urinary tract infection. Int J Antimicrob Agents 2002;20(4):297-300
58. Ferry SA, Holm SE, Stenlund H, et al. Clinical and bacteriological outcome of different doses and duration of pivmecillinam compared with placebo therapy of uncomplicated lower urinary tract infection in women: the LUTIW project. Scand J Prim Health Care 2007;25(1):49-57
59. Jardin A, Cesana M. Randomized, double-blind comparison of single-dose regimens of rufloxacin and pefloxacin for acute uncomplicated cystitis in women. French Multicenter Urinary Tract Infection-Rufloxacin Group. Antimicrob Agents Chemother 1995;39(1):215-220
60. Henry D, Ellison W, Sullivan J, et al. Treatment of community-acquired acute uncomplicated urinary tract infection with sparfloxacin versus ofloxacin. The Sparfloxacin Multi Center UUTI Study Group. Antimicrob Agents Chemother. 1998;42(9):2262-2266
61. Henry DC, Nenad RC, Iravani A, et al. Comparison of sparfloxacin and ciprofloxacin in the treatment of community-acquired acute uncomplicated urinary tract infection in women. Sparfloxacin Multicenter Uncomplicated Urinary Tract Infection Study Group. Clin Ther 1999;21(6):966-981
62. Gossius GVL. The treatment of acute dysuria-frequency syndrome in adult women: double-blind, randomized comparison of three-day vs ten-day trimethoprim therapy. Curr Ther Res 1985;37:34-42
63. van Merode T, Nys S, Raets I, Stobberingh E. Acute uncomplicated lower urinary tract infections in general practice: clinical and microbiological cure rates after three- versus five-day treatment with trimethoprim. Eur J Gen Pract 2005;11(2):55-58
64. Gossius G, Vorland L. A randomised comparison of single-dose vs. three-day and ten-day therapy with trimethoprim-sulfamethoxazole for acute cystitis in women. Scand J Infect Dis 1984;16(4):373-379
65. Raz R, Chazan B, Kennes Y, et al. Empiric use of trimethoprim- sulfamethoxazole (TMP-SMX) in the treatment of women with uncomplicated urinary tract infections, in a geographical area with a high prevalence of TMP-SMX-resistant uropathogens. Clin Infect Dis 2002;34(9):1165-1169
66. Ode B, Broms M, Walder M, Cronberg S. Failure of excessive doses of ampicillin to prevent bacterial relapse in the treatment of acute pyelonephritis. Acta Med Scand 1980;207(4):305-307
67. Giamarellou H. Low-dosage cefepime as treatment for serious bacterial infections. J Antimicrob Chemother 1993;32(Suppl B):123-132
68. Sanchez M, Collvinent B, Miro O, et al. Short-term effectiveness of ceftriaxone single dose in the initial treatment of acute uncomplicated pyelonephritis in women. A randomised controlled trial. Emerg Med J. 2002;19(1):19-22
69. Talan DA, Stamm WE, Hooton TM, et al. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis pyelonephritis in women: a randomized trial. JAMA 2000;283(12):1583-1590
70. Talan DA, Klimberg IW, Nicolle LE, et al. Once daily, extended release ciprofloxacin for complicated urinary tract infections and acute uncomplicated pyelonephritis. J Urol 2004;171(2 Pt 1):734-739
71. Talan DA, Naber KG, Palou J, Elkharrat D. Extended-release ciprofloxacin (Cipro XR) for treatment of urinary tract infections. Int J Antimicrob Agents 2004;23(Suppl 1):S54-66
72. Naber KG, Schoenwald S, Hauke W. Cefpodoxime proxetil in patients with acute uncomplicated pyelonephritis. International, prospective, randomized comparative study versus ciprofloxacin in general practice. Chemotherapie J 2001;10:29-34
73. Cronberg S, Banke S, Bergman B, et al. Fewer bacterial relapses after oral treatment with norfloxacin than with ceftibuten in acute pyelonephritis initially treated with intravenous cefuroxime. Scand J Infect Dis 2001;33(5):339-343
74. Naber KG, Llorens L, Kaniga K, et al. Intravenous therapy with doripenem versus levofloxacin with an option to switch to oral therapy for the treatment of complicated lower urinary tract infection and pyelonephritis. Antimicrob Agents Chemother 2009;53(9):3782-3792
75. Wells WG, Woods GL, Jiang Q, Gesser RM. Treatment of complicated urinary tract infection in adults: combined analysis of two randomized, double-blind, multicentre trials comparing ertapenem and ceftriaxone followed by appropriate oral therapy. J Antimicrob Chemother 2004;53(Suppl 2):ii67-74
76. Naber KG, Bartnicki A, Bischoff W, et al. Gatifloxacin 200 mg or 400 mg once daily is as effective as ciprofloxacin 500 mg twice daily for the treatment of patients with acute pyelonephritis or complicated urinary tract infections. Int J Antimicrob Agents 2004;23(Suppl 1):S41-53
77. Richard GA, Klimberg IN, Fowler CL, et al. Levofloxacin versus ciprofloxacin versus lomefloxacin in acute pyelonephritis. Urology 1998;52(1):51-55
78. Klausner HA, Brown P, Peterson J, et al. A trial of levofloxacin 750 mg once daily for 5 days versus ciprofloxacin 400 mg and/or 500 mg twice daily for 10 days in the treatment of acute pyelonephritis. Curr Med Res Opin 2007;23(11):2637-2645
79. Peterson J, Kaul S, Khashab M, et al. A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis. Urology 2008;71(1):17-22
80. Mouton YJ, Beuscart C. Empirical monotherapy with meropenem in serious bacterial infections. Meropenem Study Group. J Antimicrob Chemother 1995;36(Suppl A):145-156
81. Naber KG, Savov O, Salmen HC. Piperacillin 2 g/tazobactam 0.5 g is as effective as imipenem 0.5 g/cilastatin 0.5 g for the treatment of acute uncomplicated pyelonephritis and complicated urinary tract infections. Int J Antimicrob Agents 2002;19(2):95-103
82. Jernelius H, Zbornik J, Bauer CA. One or three weeks' treatment of acute pyelonephritis? A double-blind comparison, using a fixed combination of pivampicillin plus pivmecillinam. Acta Med Scand 1988;223(5):469-477
83. Stamm WE, McKevitt M, Counts GW. Acute renal infection in women: treatment with trimethoprim-sulfamethoxazole or ampicillin for two or six weeks. A randomized trial. Ann Intern Med 1987;106(3):341-345
84. Johnson JR, Lyons MF II, Pearce W, et al. Therapy for women hospitalized with acute pyelonephritis: a randomized trial of ampicillin versus trimethoprim-sulfamethoxazole for 14 days. J Infect Dis 1991;163(2):325-330
85. Vogel F, Naber KG, Wacha H, et al. Parenterale Antibiotika bei Erwachsenen. Chemotherapie J 1999;8:2-49